CSIMarket Company Name, Ticker, Customers, else..
 
Veru Inc   (NASDAQ: VERU)
Other Ticker:  
 
 
Price: $0.5252 $0.00 -0.057%
Day's High: $0.535 Week Perf: 0.13 %
Day's Low: $ 0.51 30 Day Perf: 5.89 %
Volume (M): 40 52 Wk High: $ 1.75
Volume (M$): $ 21 52 Wk Avg: $0.82
Open: $0.51 52 Wk Low: $0.45



 Market Capitalization (Millions $) 77
 Shares Outstanding (Millions) 146
 Employees 89
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 0

Veru Inc
Veru Inc is a biopharmaceutical company that primarily focuses on developing and commercializing drugs for men's and women's health. They work to address unmet medical needs in areas such as prostate cancer, male infertility, and sexual health. The company also offers a range of consumer healthcare products. Veru's goal is to provide innovative and effective solutions to enhance the well-being and quality of life for patients.


   Company Address: 2916 N. Miami Avenue, Suite 1000 Miami 33127 FL
   Company Phone Number: 509-6897   Stock Exchange / Ticker: NASDAQ VERU


Customers Net Income grew by VERU's Customers Net Profit Margin grew to


8.27 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        3.78% 
LLY        14.68% 
MRK   -1.49%    
SNY   -1.19%    
TEVA        3.82% 
VTRS        3.65% 
• View Complete Report
   



Clinical Study

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for E...

Published Tue, Nov 5 2024 1:30 PM UTC

Veru Inc. Unveils Promising Insights on Enobosarm and Broader Market Dynamics at ObesityWeek MIAMI, FL, Nov. 05, 2024 Veru Inc. (NASDAQ: VERU), a forward-thinking biopharmaceutical firm renowned for developing cutting-edge therapies in muscle preservation, oncology, and respiratory illnesses, recently spotlighted a noteworthy meta-analysis at the ObesityWeek conference ...
Clinical Study

s for appointing Dr. Steven B. Heymsfield as the Principal Investigator for its Phase 2b clinical trial of enobosarm....

Published Mon, Jul 29 2024 12:30 PM UTC

Veru Inc. Engages Investors at BTIG Virtual Biotechnology Conference and Makes Progress with Enobosarm Clinical Trials for High-Quality Weight Loss Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company headquartered in Miami, Florida, is at the forefront of innovation in the healthcare sector. On July 29, 2024, the company announced its participation in t...
Product Service News

Veru Announces Positive Safety and Body Composition Data from Groundbreaking Studies Presented at American Diabetes A...

Published Mon, Jun 24 2024 12:30 PM UTC

MIAMI, FL - Veru Inc. (NASDAQ: VERU), a leading biopharmaceutical company focused on developing groundbreaking medicines for muscle preservation, weight loss, oncology, and viral-induced acute respiratory distress syndrome, has unveiled significant findings from two late-breaking presentations at the esteemed American Diabetes Association s 84th Scientific Sessions in Orland...
Clinical Study

Veru Inc. Showcases Promising Presentations at ADA Scientific Sessions while Dealing with Revenue Challenges

Published Mon, Jun 10 2024 12:30 PM UTC

Combining the articles, we get the following sophisticated article:Veru to Present at the American Diabetes Association s 84th Scientific SessionsMIAMI, FL, June 10, 2024 - Veru Inc. (NASDAQ: VERU), a leading biopharmaceutical company specializing in innovative medications for muscle preservation in weight loss, oncology, and viral induced acute respiratory distress syndrome...
Clinical Study

Veru Inc. Appoints Leading Physician to Spearhead Enobosarm Clinical Trial for High-Quality Weight Loss

Published Wed, May 15 2024 12:30 PM UTC

Veru Inc. Announces Steven B. Heymsfield as Principal Investigator for Enobosarm Phase 2b Clinical Trial for High-Quality Weight LossMIAMI, FL, May 15, 2024 - Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company dedicated to developing innovative medicines for high-quality weight loss, oncology, and viral-induced acute respiratory distress syndrome, has ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com